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Mycobacterium tuberculosis synthesizes isoprenoids via the nonmevalonate or DOXP pathway. Previous work
demonstrated that three enzymes in the pathway (Dxr, IspD, and IspF) are all required for growth in vitro. We
demonstrate the essentiality of the key genes dxs1 and gcpE, confirming that the pathway is of central
importance and that the second homolog of the synthase (dxs2) cannot compensate for the loss of dxs1. We
looked at the effect of overexpression of Dxr, Dxs1, Dxs2, and GcpE on viability and on growth in M.
tuberculosis. Overexpression of dxs1 or dxs2 was inhibitory to growth, whereas overexpression of dxr or gcpE was
not. Toxicity is likely to be, at least partially, due to depletion of pyruvate from the cells. Overexpression of dxs1
or gcpE resulted in increased flux through the pathway, as measured by accumulation of the metabolite
4-hydroxy-3-methyl-but-2-enyl pyrophosphate. We identified the functional translational start site and pro-
moter region for dxr and demonstrated that it is expressed as part of a polycistronic mRNA with gcpE and two
other genes. Increased expression of this operon was seen in cells overexpressing Dxs1, indicating that
transcriptional control is effected by the first enzyme of the pathway via an unknown regulator.
Mycobacterium tuberculosis, the causative agent of human
tuberculosis, poses an increasing threat to health. The escalat-
ing incidence of drug resistant strains provides a new impetus
to understand this complex pathogen and to identify metabolic
targets for novel therapeutics. As a first step toward this aim,
we have been directing our efforts to identifying metabolic
pathways essential for bacterial viability.
Several of the current antibiotics active against M. tuberculosis
target cell wall biosynthesis, in particular the synthesis of mycolic
acids (inhibited by isoniazid and ethionamide) or arabinogalactan
and lipoarabinomannan (inhibited by ethambutol). Isoprenoid
biosynthesis is a key synthetic pathway required for the genera-
tion of many cellular components, including cell wall components.
M. tuberculosis synthesizes the isoprenoid precursor, isopentenyl
diphosphate (IPP), via the nonmevalonate or 1-deoxy-D-xylulose
5-phosphate (DOXP) pathway, in contrast to the human meval-
onate pathway. Therefore, the bacterial enzymes can be specifi-
cally targeted without interfering with eukaryotic isoprenoid bio-
synthesis, making this an attractive pathway in the search for
novel drugs.
The DOXP pathway has been characterized in several bac-
terial species; all of the genes can be identified by homology in
the M. tuberculosis genome, and the proposed pathway can be
reconstructed (Fig. 1). Recombinant proteins have been pro-
duced, and enzymatic activities have been confirmed for Dxs1
(2), Dxr (11, 18), IspD (14), and IspF (7). In addition, previous
work demonstrated that Dxr, IspD, and IspF are all essential
for the in vitro growth of M. tuberculosis (6, 7, 14). M. tubercu-
losis genome has two homologs of dxs (dxs1, Rv2682c; and
dxs2, Rv3379c) and lytB (lytB1, Rv3382c; and lytB2, Rv1110).
The presence of two homologs of Dxs is also seen in the closely
related actinomycete Streptomyces coelicolor (8), where both
enzymes are functional. In contrast, in M. tuberculosis only
Dxs1 (Rv2682c) is a functional DOXP synthase (2).
The DOXP pathway has been implicated in the pathogenic
potential of mycobacterial species. Disruption of the lytB1-dxs2
operon in M. tuberculosis abolishes the bacterial ability to pre-
vent acidification of the phagosome and results in attenuated
intracellular survival (30). In addition, an M. avium subsp.
paratuberculosis gcpE mutant is less able to colonize tissue
during infection of mice or calves (35, 36), confirming that this
pathway is required for virulence. However, in both cases, it is
yet to be determined whether this is a direct link between
isoprenoid biosynthesis and the phenotypic consequences,
since no measure of IPP synthesis was made.
In contrast to the biochemical characterization, little is
known about the regulation of expression of the DOXP path-
way genes or the control of flux through the pathway in M.
tuberculosis. In M. tuberculosis, as with other organisms, DOXP
pathway genes are distributed throughout the genome, with no
apparent motif for any recognized global regulator. Few clues
as to the regulation of this pathway are found in other organ-
isms, and no transcriptional regulators have been identified.
Several of the DOXP genes appear to be located in operons:
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dxr is located in an apparent operon with gcpE and two other
genes (rip and gcn5), ispD and ispF appear to be part of a
bicistronic operon, and lytB1 appears to be in an operon with
idsB and possibly dxs2. The remaining genes (ispF, dxs2, and
lytB2) are expressed as monocistronic units (Fig. 2). Changes in
gene expression have been observed after antibiotic exposure
(4) and LytB is downregulated in a cytochrome bc1 mutant of
Mycobacterium smegmatis (25).
In the present study we investigated the essentiality and
regulation of key members of the DOXP pathway in M. tuber-
culosis (Dxs, Dxr, and GcpE). We confirmed that Dxs1 and
GcpE are essential and that Dxs2 cannot complement for the
functional loss of Dxs1. Since essential genes by definition
cannot be deleted from the cell, we looked at the effect of
overexpression of these enzymes on the viability and pheno-
typic characteristics of the bacilli. We also investigated the
organization and expression of the dxr operon.
MATERIALS AND METHODS
For primer sequences and plasmid descriptions, see Tables S1 and S2 in the
supplemental material.
Culture of mycobacteria. M. tuberculosis H37Rv was cultured in Middlebrook
7H9 liquid medium supplemented with 10% (vol/vol) OADC (oleic acid, bovine
serum albumin, D-glucose, catalase; Becton Dickinson) and 0.05% (wt/vol)
Tween 80 or on solid Middlebrook 7H10 agar supplemented with 10% (vol/vol)
OADC at 37°C. For overexpression studies using the acetamidase promoter, 7H9
medium was supplemented with 0.2% (wt/vol) succinate, 0.5% (wt/vol) bovine
serum albumin (BSA) (uninduced) or with 0.2% succinate, 0.2% (wt/vol) acet-
amide, and 0.5% (wt/vol) BSA (induced) instead of OADC. M. smegmatis
mc2155 was grown on Lemco medium (33). X-Gal (5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) was used at 50 g/ml, IPTG (isopropyl--D-thiogalacto-
pyranoside) at 0.5 mM, kanamycin at 20 g/ml, hygromycin B at 100 g/ml,
gentamicin at 10 g/ml, and sucrose at 2% (wt/vol) where required. M. tubercu-
losis growth curves were conducted in 16-mm glass tubes containing an 8-mm
magnetic stirrer bar with stirring at 150 rpm.
Determination of essentiality. Deletion delivery vectors for dxs1, dxr, and gcpE
were constructed as follows. First, 1 kb of the flanking regions surrounding
each gene was amplified from M. tuberculosis genomic DNA using primer pairs
(US/DS). Fragments were cloned into p2NIL using the PstI-HindIII restriction
sites (28). The 6.3-kb PacI cassette from pGOAL19 (28) (hyg, sacB, and lacZ)
was cloned into the sole PacI site. Vectors were verified by restriction digest and
sequencing. 5 g of UV pretreated plasmid DNA (27) was electroporated into
competent M. tuberculosis (15), and single-crossover (SCO) transformants were
selected on medium containing kanamycin, hygromycin, and X-Gal. Comple-
menting vectors carrying a functional copy of the gene were made for dxs1 (under
the control of Ag85A promoter in pAPA3 [26]) and for dxr and gcpE (the
complete operon together with the native promoter [6]). Merodiploid strains
were constructed by electroporating the SCO strains with the appropriate com-
plementing plasmids and isolating kanamycin-, hygromycin-, and gentamicin-
resistant transformants. Double crossovers (DCOs) were isolated in the wild-
type and merodiploid background by streaking cells onto plates lacking
antibiotics and selected/screened on medium containing sucrose, X-Gal, and
gentamicin where required as previously described (28). PCR screening to de-
termine which allele (wild-type or deletion) was present in the chromosomal
location was carried out using gene-specific screening primers. The genotype of
selected strains were confirmed by Southern analysis using the AlkPhos Direct
system (GE Healthcare) according to the manufacturer’s instructions.
Gene switching. Gene switching was carried out as previously described (5,
29). Strains carrying integrated plasmids were electroporated with an integrating
plasmid bearing an alternative selection marker, and transformants were isolated
by selecting for the incoming plasmid. Switching was confirmed by patch testing
for the loss of the appropriate resistance.
Construction of overexpression strains. dxs1, dxs2, dxr (expressed from the
first possible start codon), dxrt (truncated dxr, expressed from the last possible
start codon), and gcpE were amplified using gene specific primers with Pfu
DNA polymerase and cloned into pSMT3 under the control of the strong,
constitutive hsp60 promoter from Mycobacterium bovis (19) or into pJFR19,
under the control of the inducible acetamidase gene from M. smegmatis (10).
Constructs were introduced into M. tuberculosis via electroporation (15) and
selected on plates containing hygromycin. Three independent transformants
were selected for each plasmid. Overexpression was confirmed by reverse
transcription-PCR (RT-PCR).
Construction of dxr expression vectors. dxr was amplified and cloned into
pBAD202 (Invitrogen). Insert integrity was confirmed by sequencing. Growth
was measured in transformants grown in half-strength LB with various concen-
trations of arabinose. The truncated dxr gene (dxrt) was amplified and cloned into
FIG. 1. DOXP pathway of isoprenoid biosynthesis in M. tuberculo-
sis. The metabolic pathway from Dxs to LytB is shown. Enzyme names
are given with the corresponding H37Rv gene numbers in parentheses.
IPP, isopentenyl phosphate; DMAPP, dimethylallyl pyrophosphate
HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate is boxed.
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pBAD202 or pSMT3. Plasmids were introduced into M. smegmatis and M.
tuberculosis via electroporation and selected on hygromycin. Three independent
transformants were analyzed for each vector.
RT-PCR. RNA was prepared from M. tuberculosis standing cultures as previ-
ously described and DNase treated (34). cDNA was synthesized from 1 g of
total RNA using SuperScript II RT (Invitrogen) and random primers according
to the manufacturer’s instructions. An RT-minus control for each sample was
also included and processed in tandem. Cycling conditions were 30 cycles of 94°C
for 30, 56°C for 30, and 72°C for 1 using GoTaq PCR Mastermix (Promega).
The amplified products were run on a 1% agarose gel and visualized with
ethidium bromide.
Promoter analyses. The upstream regions of dxr and gcpE were amplified
and cloned into the integrating promoter reporter vector pSM128 (12). Plas-
mids were electroporated into M. tuberculosis and transformants selected on
streptomycin. Three transformants for each were used to inoculate standing
cultures. Cell extracts and -galactosidase assays were performed as de-
scribed previously (9).
Semiquantitative RT-PCR analysis. We used limiting dilution RT-PCR to
determine mRNA levels (31). PCR was carried out using undiluted cDNA and
serial fourfold dilutions (1:4, 1:16, 1:64, 1:256, and 1:1,026) using RT primers for
dxs1, dxs2, dxr, gcpE, and sigA. The cycling conditions were 30 cycles of 94°C for
30, 56°C for 30, and 72°C for 1 using GoTaq PCR Mastermix (Promega). The
amplified products were run on a 1% agarose gel and visualized with ethidium
bromide.
Macrophage infection assays. Macrophage infection assays were carried out
using human monocytic leukemia cell line (THP-1) (ATCC–TIB-202) as de-
scribed previously (23). Determination of the initial inoculum was assessed by
plating serial dilutions and the number of intracellular bacteria was monitored
over 7 days.
HMB-PP assays using stimulation of  cells. Strains were cultured aerobi-
cally in 100 ml of medium in roller bottles for 7 days. Cells were harvested by
centrifugation at 4,000  g, washed twice with 10 ml of 10 mM Tris (pH 7.5),
resuspended in 1 ml of 10 mM Tris (pH 7.5), and transferred to Lysing Matrix B
tubes (MP Biomedicals). Cells were disrupted using a FastPrep (MP Biomedi-
cals) at speed 6.5 for 40 s and passed through a 0.2-m-pore-size filter. Protein
concentrations were measured by using a BCA protein concentration kit (Pierce)
and adjusted to 0.5 mg/ml. Low-molecular-weight filtrates for stimulation assays
were prepared by passing the cell-free effluents through 0.1-m-pore-size Du-
rapore polyvinylidene difluoride Ultrafree-MC and 3,000 MWCO regenerated
cellulose Ultracel-YM3 filters (Millipore), as previously described (13). PBMC
were cultured in RPMI 1640 supplemented with 2 mM L-glutamine, 1% nones-
sential amino acids, 1% sodium pyruvate, 50 g of penicillin-streptomycin/ml, 50
M -mercaptoethanol, and 10% fetal calf serum (Invitrogen). A total of
200,000 PBMC per well were stimulated by addition of serial dilutions of syn-
thetic 4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) (32) or low-mo-
lecular-weight filtrates, in the presence of 20 to 100 U of recombinant interleu-
kin-2 (Proleukin; Chiron)/ml.  T-cell activation was determined by measuring
the upregulation of CD25 and CD69 on the cell surface and the expansion of
V9/V  2 T cells over 6 days, and the bioactivity of the bacterial preparation was
expressed as micrograms of HMB-PP per gram of protein, as described previ-
ously (13).
RESULTS
dxs1 and gcpE are essential for in vitro growth of M. tuber-
culosis. Several genes encoding enzymes of the DOXP pathway
are essential for the viability of M. tuberculosis in culture (6, 7,
14). However, we had not previously investigated dxs1 or gcpE.
We attempted to construct in-frame, unmarked deletions for
each gene in a wild-type background and in a merodiploid
background (in which a functional copy of the gene was pro-
vided on an integrating plasmid). For both genes we were
unable to isolate chromosomal deletions strains in the wild-
type background (n 	 40 for each gene). We confirmed that
both genes were essential by obtaining chromosomal deletions
of dxs1 and gcpE when the second copy of the gene was intro-
duced (20 of 40 and 23 of 40 strains tested were deletion alleles
for dxs1 and gcpE, respectively). The expected genotypes of
selected strains were confirmed by Southern analysis (data not
shown).
The essentiality of dxr has been demonstrated in our labo-
ratory, but the strain generated during this process had a de-
letion in which the upstream region of dxr, as well as dxr itself
and the start codon of the downstream gene rip, was deleted
(6). Since we wanted to have a strain in which dxr alone was
deleted for further analysis, we constructed a second deletion
delivery vector (in which dxr was deleted and the promoter
region and adjacent genes remained intact). Using this dele-
tion vector, we confirmed our previous results demonstrating
the essentiality of dxr in that we were unable to obtain a
chromosomal deletion in the wild-type background (40 strains
tested) but were able to do so in the merodiploid (19 of 40
FIG. 2. Genomic organization of the DOXP genes. The chromosomal arrangement is indicated. DOXP pathway genes are in black. The genetic
coordinates for the H37Rv strain of M. tuberculosis are given.
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strains tested). The expected genotypes of selected strains were
confirmed by Southern analysis (data not shown).
We further confirmed essentiality of all three genes using
gene switching to demonstrate that the complementing vector
could not be removed when the chromosomal gene copy had
been deleted (5, 29). We attempted to replace the comple-
menting vector with an empty vector (pUC-Hyg-Int) (24) car-
rying a different resistance marker (hyg). We did not obtain any
transformants in which the resident complemented vector was
replaced by pUC-Hyg-Int for any of the genes. Controls in
which the empty vector was switched into the merodiploid
strains (where the chromosomal gene copy was still intact and
an integrated copy was present) gave a typical switching effi-
ciency of 107/g. These data confirm that viability is dependent
on the presence of the complementation vector for all three
genes. Therefore, we were able to conclude that in addition to
dxr, dxs1, and gcpE are essential for the in vitro growth of M.
tuberculosis.
We also attempted to make deletion mutants of dxs2. We
used a number of alternative deletion delivery constructs but
were unable to obtain single crossovers without rearrange-
ments in the chromosome. This is likely to be caused by the
presence of an insertion element in the area; since our deletion
constructs also contained the insertion element, it could easily
lead to problems with rearrangements and recombination be-
tween repeat elements.
Overexpression of Dxs1 or Dxs2, but not GcpE, is inhibitory
to growth in M. tuberculosis. Since we had confirmed that Dxr,
Dxs1, and GcpE are all essential for the viability of M. tuber-
culosis in culture, we were unable to construct deletion mu-
tants for phenotypic studies. Instead, we decided to look at the
effect of overexpression of each. We first attempted to over-
express Dxs1 and Dxs2 independently; plasmids carrying either
dxs1 or dxs2 under the control of the strong, constitutive hsp60
promoter were constructed and transformed into M. smegmatis
and M. tuberculosis. No transformants were obtained on sev-
eral occasions, suggesting that high level expression was toxic
to the cells. We therefore constructed alternative expression
vectors in pJFR19 under the control of the inducible acetami-
dase gene from M. smegmatis (10). The acetamidase promoter
has a basal level of activity in the “noninduced” state and is
further upregulated by the addition of acetamide; thus, over-
expression is normally achieved in the absence of induction but
can be boosted by the addition of the inducer acetamide.
We looked at the effect of overexpression of dxs1 and dxs2
using the acetamidase promoter expressing at the basal level
and after further induction by acetamide in M. tuberculosis
(Fig. 3). Growth was slightly retarded regardless of the addi-
tion of inducer, which could be explained since expression
from the acetamidase promoter is leaky (10, 33). Overexpres-
sion had a slightly detrimental effect on the growth of M.
tuberculosis (Fig. 3), suggesting that high level expression of
either of the two Dxs enzymes is toxic. This was particularly
interesting given that recombinant Dxs2 does not have DOXP
synthase activity (2) and suggests that it may have an alterna-
tive, as-yet-unidentified function. This effect was specific to
Dxs1/Dxs2, since overexpression of GcpE did not result in
retarded growth (data not shown).
We also looked at the effect of Dxs overexpression on other
phenotypes that could be affected by changes in cell wall syn-
thesis, but no effect on antibiotic resistance (rifampin, isonia-
zid, novobiocin, ethambutol, and ampicillin), gross colony mor-
phology, or replication in macrophages was seen (data not
shown).
We used the same strategy to overexpress gcpE from the
hsp60 promoter. No problems were seen with toxicity and
plasmids were easily transformed into M. smegmatis and M.
tuberculosis. No effect on growth in liquid culture, antibiotic
resistance or gross colony morphology was found, nor was
there any defect in or replication in macrophages (data not
shown).
Overexpression of Dxr in Escherichia coli and mycobacteria.
We also looked at the effect of overexpression of Dxr. Our
initial attempts to clone dxr into routine cloning vectors
(pGEM T-Easy, pSMT3, and pJRF19) failed. We either ob-
tained no transformants, or the few transformants found had
mutations in the coding sequence. This suggested that the
clone was toxic to E. coli and could not be tolerated. In order
to overcome potential toxicity we cloned dxr under the control
of the tightly repressed arabinose promoter using the pBAD
system in which the protein is expressed as a thioredoxin fusion
protein. Plasmids were easily obtained without mutations in
the dxr coding sequence. We assessed growth in E. coli with
increasing concentrations of arabinose to induce expression of
FIG. 3. Overexpression of Dxs1 or Dxs2 is inhibitory to growth in mycobacteria. Transformants overexpressing Dxs1 or Dxs2 were grown in
liquid medium under noninduced (S 	 succinate) or induced (AS 	 acetamide, succinate) conditions. Symbols: }, control vector pJFR19; f,
dxs1-overexpressing vector; F, dxs2-overexpressing vector. The results are expressed as the means and standard deviations of three independent
transformants.
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dxr; this clearly had a toxic effect and inhibited growth (Fig. 4).
We hypothesized that toxicity could be due to depletion of
pyruvate from the cells, since this is the substrate of the path-
way. Addition of 0.5% sodium pyruvate to the medium par-
tially relieved toxicity, allowing increased cell growth in the
presence of elevated Dxr expression, but it did not completely
reverse the phenotype (Fig. 4). Thus, the toxicity was not
wholly dependent on Dxr enzyme activity.
The translational start site for Dxr has not been identified by
experimental means and could be any one of five initiation
codons (Fig. 5). In our attempts to clone dxr, we initially am-
plified a region containing all of these potential start codons, to
ensure production of a full-length protein. In addition, previ-
ous work with enzymatically active Dxr was achieved using a
shorter version (11). We decided to attempt to clone a smaller
fragment of DNA starting at the sequence from the putative
start codon furthest downstream. We cloned this short frag-
ment into the arabinose-controlled system (pBAD) and as-
sessed toxicity in E. coli. Overexpression of Dxr from this
construct was not toxic for E. coli (Fig. 5). Since this version
was tolerated, we cloned the region into the pSMT3 overex-
pression vector and easily isolated a recombinant plasmid with
no mutations in dxr. The resultant plasmid transformed M.
smegmatis and M. tuberculosis at a high efficiency. Growth
curves for M. smegmatis and M. tuberculosis demonstrated no
change in growth rate after Dxr overexpression; no effect on
antibiotic resistance, gross colony morphology or replication in
macrophages was seen (data not shown). Thus, the original
toxicity noted appears to derive from inclusion of the upstream
region.
Determination of the translational start site of Dxr. Our
results showed that the inclusion of the upstream region of Dxr
construct resulted in toxicity. Since expression of the clone in
pBAD results in a fusion protein by virtue of the cloning
method, the upstream region would be translated into protein,
and this itself could be responsible for a toxic effect. In order
to determine whether this had any bearing on the normal
expression of Dxr and whether the native protein might con-
tain a toxic N terminus, we wanted to identify which of the five
potential translational start sites were utilized in M. tuberculo-
sis. In order to identify which start codon is used in the native
host, we used two approaches.
First, we determined the 5 limit of transcription for the dxr
gene transcript in M. tuberculosis. RNA was isolated from M.
tuberculosis and subjected to RT-PCR using primers designed
to amplify different regions at the 5 end of dxr. An amplifica-
tion product was obtained with one set of primers only, dem-
onstrating that the shorter transcript is the only one present
and that the region upstream is not transcribed (Fig. 5).
Second, we looked at the functionality of the translational
start codons in M. tuberculosis. We made use of the strain we
had constructed in which the chromosomal copy of dxr is de-
leted and the only functional copy is present on the integrating
vector (which could be replaced). A number of complementing
vectors were constructed, in which each putative start codon
was mutated to alanine (Fig. 5). Vectors were tested for func-
tional complementation of the chromosomal deletion by gene
switching, i.e., we replaced the sole functional copy with the
mutant allele. Functional complementation was obtained with
five of the six mutant constructs; the only construct that failed
to complement was that with the furthest downstream V-to-A
mutation. We also constructed a mutation in which a stop
codon was introduced immediately upstream; this vector was
able to functionally complement the deletion. These data con-
firm that the distal site is the functional translational start site
in M. tuberculosis.
Dxr is expressed as an operon with GcpE. Dxr appears to be
expressed as an operon with three other genes (Fig. 2) since
the gaps between the genes are small, although the ORFs do
not overlap. In order to define whether the genes are cotrans-
cribed as an operon, we conducted RT-PCR to look at coex-
pression of each pair of genes. Primers were designed to am-
plify the junctions between dxr/rip, rip/gcpE, and gcpE/gcn5 and
used on cDNA from M. tuberculosis; in each case a specific
FIG. 4. Induction of Dxr expression results in growth inhibition in E. coli, which is partially relieved by pyruvate addition. The growth of
transformants expressing Dxr from the arabinose-inducible pBAD plasmid was measured. (A) Inhibition of growth in response to increased Dxr
expression. Growth was measured in half-strength LB medium. Various concentrations of arabinose (g/ml) were used to induce expression from
the pBAD promoter, and growth was measured after 4 h. (B) Relief of toxicity by pyruvate. Strains were grown in the presence of various
concentrations of arabinose (indicated in g/ml). , No sodium pyruvate; f, plus 0.5% sodium pyruvate. Growth was measured after 20 h.
(C) Truncated Dxr is not toxic. Strains carrying the full-length (“Dxr”) or truncated (“tDxr”) constructs were grown in the presence of no arabinose
() or 1% arabinose (f) to induce expression. Growth was measured after 20 h. The results are expressed as the means of three independent
transformants.
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product was detected, indicating that the four genes are co-
transcribed and form a bona fide operon (Fig. 6).
We also identified the promoter region of the operon. We
amplified the region upstream of dxr and tested it for promoter
activity using a LacZ reporter. Significant promoter activity
(204 
 20 Miller units) was detected in the upstream region
confirming that a promoter is present (Fig. 6). Since we were
particularly interested to know whether dxr and gcpE were
coexpressed, we also tested the region upstream of gcpE for
promoter, but none was detected (2.2 
 0.4 Miller units; con-
trol plasmid 2.8 
 0.2 Miller units), indicating that there is not
an alternative functional promoter (Fig. 6).
Although our data demonstrated that there was no promoter
activity from the region upstream of gcpE, and that gcpE would
be coexpressed with dxr, we considered that there was the
possibility that a promoter could exist which was only func-
tional under specific conditions. Therefore, we used a func-
tional assay for the expression of gcpE in cells. We used the M.
tuberculosis strain in which the dxr promoter (and dxr) was
deleted and where functional complementation was provided
by the complete dxr operon (6). In this strain the remainder of
the dxr operon was intact, including gcpE and its upstream
region. We constructed a complementing vector, in which gcpE
was deleted from the operon and tested it for functional
complementation by gene switching. No viable colonies were
isolated, indicating that gcpE was not being expressed from the
chromosomal location. In control switching experiments in
which the same vector was used, but the strain background was
wild type, a transformation efficiency of 108 per g of plasmid
DNA was achieved. Thus, we confirmed that in the normal
chromosomal location gcpE is expressed from the promoter
upstream of dxr and that this represents a functional operon.
Overexpression of DOXP genes leads to the accumulation of
HMB-PP. Many synthetic pathways are subject to posttransla-
tional control with the first enzymatic reaction being a regula-
tory step controlling flux through the pathway by, for example,
feedback inhibition of enzyme activity by the end product.
In order to assess the effect on flux through the synthetic
pathway resulting from overexpression of enzymes from either
the beginning or the end of the pathway, we measured accu-
mulation of one of the end products of the pathway; HMB-PP
is the product of the GcpE-catalyzed reaction and can be
measured using a biological assay (stimulation of  T cells)
(13).
We used this assay to measure changes in HMB-PP levels in
the overexpressing strains (Fig. 7). As expected, Dxs2 overex-
pression did not affect HMB-PP levels, since it is not a func-
tional enzyme. In contrast, overexpression of either Dxs1 or
FIG. 5. Determination of the correct translational start site for Dxr. (A) The upstream region of Dxr is shown, indicating the region included
in the full-length, toxic clone (wDxr) and the shorter clone (tDxr). Potential translational start sites are boxed. The upstream primers used for
RT-PCR are indicated. (B) RT-PCR analysis of the dxr transcript. RNA was isolated from wild-type M. tuberculosis, cDNA was synthesized and
amplified with the indicated primers plus a common downstream primer: , plus RT; N, no RT; B, blank (no template); and G, genomic DNA.
(C) Functional analysis of the Dxr start codon. Mutations were made in the upstream region as indicated in boldface underline and tested for
functionality using gene switching. The potential translated sequence is shown, pOPH encodes the wild-type sequence.
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GcpE led to a twofold increase in HMB-PP levels over the wild
type. Overexpression of Dxr had no effect. These results were
unexpected, in that we found overexpression of the first or last
enzyme, but not the intermediate enzyme led to increased end
product accumulation. Normally, one enzyme will be the rate-
limiting step in the metabolic pathway, and this choke point
would determine flux through the pathway. For example, if Dxs
were the limiting step, then overexpression of GcpE should
make no difference to HMB-PP accumulation; similarly, if
GcpE were the limiting step, then overexpression of Dxs would
have no effect. This led us to hypothesize that regulatory con-
trol over and above enzymatic activity was occurring, possibly
at the level of transcription.
Overexpression of Dxs leads to upregulation of the Dxr
operon. In order to address this possibility that overexpres-
sion of one enzyme could lead to transcriptional changes, we
looked at the level of expression of Dxs1, Dxr and GcpE in
the overexpressing strains. For each strain, we confirmed
that the expected genes were being overexpressed from the
plasmid constructs; levels of overexpression were approxi-
mately 16-fold under induced conditions (Fig. 8). The data
also confirmed that all of the genes were expressed in the
wild-type strain.
Overexpression of Dxr or GcpE showed no increase in the
expression levels of the other genes tested. In contrast, over-
expression of Dxs1 and Dxs2 led to increased levels of dxr
transcripts (Fig. 8); for Dxs1 it also resulted in increased levels
of gcpE transcripts. These data explain how Dxs1 overexpres-
sion leads to increased production of HMB-PP, since it also
results in the upregulation of GcpE, the last step of the path-
way. gcpE was not increased in the Dxs2-overexpressing strain,
but the amplification product showed some degree of smear-
ing, suggesting that the mRNA was being degraded from the 3
end; since GcpE is not upregulated in this strain it would
account for the lack of increase in HMB-PP in this strain. In
addition, Dxs2 was downregulated in dxs1- and dxr-overex-
pressing strains. From these data we would therefore predict
that GcpE is the rate-limiting step, but that Dxs1 and Dxs2 are
involved in transcriptional control and thus control flux at the
start point.
FIG. 6. Dxr is part of a multicistronic operon containing gcpE. (A) The dxr operon is shown. The upstream regions (0.2 kb) of dxr and gcpE
tested for promoter activity are indicated. The results are the mean -galactosidase activities (
 the standard deviations) for three independent
transformants assayed in duplicate in Miller units. The activity from the control plasmid pSM128 was 2.8 
 0.2 Miller units. (B) Cotranscription
of the dxr operon was confirmed by RT-PCR using primers to amplify the junctions between each gene pair indicate in panel A. Primers were
designed to amplify across the gene junctions; the potential amplification products are marked on the operon. , Plus RT; N, no RT; B, blank (no
template); G, genomic DNA.
FIG. 7. Overexpression of Dxs1 and GcpE leads to increased levels
of HMB-PP. M. tuberculosis strains overexpressing Dxs1, Dxs2, Dxr, or
GcpE were analyzed for HMB-PP content using an assay for stimula-
tion of  T cells. The results are the mean 
 the standard deviation
of extracts from three individual transformants. The results are ex-
pressed relative to levels in the wild-type strain. Dxs1 and Dxs2 were
expressed from the acetamidase promoter and assayed under inducing
conditions. tDxr (dxrt) and GcpE were expressed from the constitutive
hsp60 promoter. WT, wild-type M. tuberculosis.
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DISCUSSION
The DOXP pathway of isoprenoid biosynthesis is an attrac-
tive target in the search for novel therapeutics. Successful
targeting of this pathway in other organisms has already been
achieved, since the antibiotic fosmidomycin inhibits Dxr. The
majority of the genes of the pathway are essential, and there-
fore this is a crucial metabolic pathway in M. tuberculosis wor-
thy of further study.
GcpE is essential in many other species, including E. coli (1),
which rely on the DOXP pathway as the sole biosynthetic
pathway for isoprenoids, and we have demonstrated that this
also holds true for M. tuberculosis. Surprisingly, inactivation of
gcpE by transposon mutagenesis has been achieved in M.
avium subsp. paratuberculosis (35), raising the possibility that
there are other pathways for isoprenoid synthesis in this spe-
cies but not M. tuberculosis.
M. tuberculosis is unusual in that it possesses two homologs
of the DOXP synthase. Dxs1 is a fully functional enzyme, but
recombinant Dxs2 has no synthase activity due to an N-termi-
nal truncation resulting in the loss of a critical histidine residue
(2). Our data demonstrate that as expected Dxs1 is the key
enzyme in the synthetic pathway, being essential for in vitro
growth, and shows that its loss cannot be complemented for by
Dxs2.
Overexpression of both dxs1 and dxs2 had a slightly detri-
mental effect on growth of M. tuberculosis. High-level expres-
sion of recombinant Dxs is reported to result in reduced
growth in E. coli; this phenotype was attributed to a drain of
metabolites (21). Similarly, in M. tuberculosis, Dxs1 overex-
pression could deplete the substrates pyruvate and glyceralde-
hyde-3-phosphate (G3P), crucial cellular components required
for the production of acetyl coenzyme A, glycolysis, and other
metabolic pathways. However, this cannot account for growth
inhibition by Dxs2, given that dxs2 does not encode a func-
tional enzyme. However, the differences were small, so it re-
mains to be determined whether this results from increased
enzyme activity or from a general stress resulting from protein
overexpression.
Increases in flux through the pathway, as measured by pro-
duction of HMB-PP were seen after overexpression of GcpE
or Dxs1. We hypothesize that GcpE is the limiting step of the
pathway, and therefore overexpression will lead to increased
flux. In contrast increased flux after Dxs1 overexpression re-
sults from a concomitant increase in GcpE expression. This is
the first demonstration of a link between activity of an enzyme
in the DOXP pathway and transcriptional regulation of the
pathway. Dxs has been previously implicated as the rate-lim-
iting step for the synthesis of IPP in E. coli strains engineered
to overproduce lycopene (16, 20). In contrast, we found that
GcpE is the bottleneck in M. tuberculosis and that Dxs appears
to regulate flux through the pathway by mediating transcrip-
tional control of GcpE, once again, indicating how mycobac-
terial systems differ from those of other bacteria (3). Interest-
ingly, Dxs2 also caused transcriptional changes, despite having
no enzyme activity; this suggests that regulation is not due to
accumulation of the product of Dxs, but another mechanism
(2). Future work to identify the regulatory proteins and mech-
anisms could cast light on the control of isoprenoid synthesis.
It is possible that the level of expression of the enzymes is
linked to avoid the accumulation of toxic intermediates. For
example, in E. coli expressing the mevalonate pathway, toxicity
is seen due to the production of the intermediate 3-hydroxy-
3-methylglutaryl-coenzyme A (22).
The regulatory control mechanisms of the DOXP pathway
have not been elucidated in any system, although in E. coli,
expression of all of the pathway genes from dxs to gcpE on an
FIG. 8. Quantitation of expression levels of DOXP pathway genes in overexpressor strains. Limiting dilution RT-PCR was carried out with gene
specific primers for dxs1, dxs2, dxrt, and gcpE on cDNA made from the overexpressing strains. Serial 4-fold dilutions (1:1, 1:4, 1:16, 1:64, 1:256, and
1:1,024) of cDNA were used as a template for PCR with gene-specific primers. (A) Gel pictures obtained after PCR, showing product intensity
from increasing diluted cDNA; (B) relative expression levels for each gene. RNA input was standardized using sigA expression; values were then
normalized to the WT value to give an indication of the relative fold difference. WT, wild-type H37Rv; Dxs1 (NI), strain expressing dxs1 from
acetamidase promoter in noninducing conditions (basal level); Dxs1 (I), strain expressing dxs1 from acetamidase promoter in inducing conditions.
Dxs2 (NI), strain expressing dxs2 from acetamidase promoter in noninducing conditions (basal level); Dxs2 (I), strain expressing dxs2 from
acetamidase promoter in inducing conditions. Dxr, strain constitutively overexpressing dxrt from the hsp60 promoter; GcpE, strain constitutively
overexpressing gcpE from the hsp60 promoter; gDNA, genomic DNA control.
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artificial operon results in increased levels of HMB-PP (17).
We have shown that overexpression of dxs1 results in increased
HMB-PP, mediated by increased transcription of the dxr
operon, including gcpE. Overexpression of Dxr or GcpE did
not result in upregulation of the dxr operon, indicating that
only Dxs affects the transcriptional regulatory control. Other
mycobacteria (M. smegmatis, M. bovis, Mycobacterium mari-
num, and Mycobacterium leprae) also have a similar genetic
arrangement with an apparent operon including dxr and gcpE.
However, this arrangement does not seem to be present in
other bacterial species.
The DOXP biosynthetic pathway of M. tuberculosis is spe-
cific and essential and represents an attractive potential target
for the design of new antimycobacterial agents. Several DOXP
genes are located in operons, representing controlled tran-
scription, and dxr and gcpE are cotranscribed from a single
promoter element upstream of dxr. Tight regulation of Dxs
appears to be required to prevent depletion of essential com-
ponents from the cell, as demonstrated by a reduced growth
phenotype due to Dxs overexpression. Flux through the path-
way appears to be regulated by Dxs at the transcriptional level,
since unusually it appears that it directly affects transcription of
other DOXP genes. Future work to identify the regulator
would shed further light on regulation of this key pathway.
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